Avanafil
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Avanafil |
| DrugBank ID | DB06237 |
| Brand Names (EU) | Spedra |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 94.59% |
Approved Indication (EMA)
Treatment of erectile dysfunction in adult men. In order for Spedra to be effective, sexual stimulation is required.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | amenorrhea (disease) | 94.59% | DL |
| 2 | erectile dysfunction (disease) | 93.42% | DL |
| 3 | hypoalphalipoproteinemia | 91.54% | DL |
| 4 | infectious bovine rhinotracheitis | 90.62% | DL |
| 5 | malignant catarrh | 90.62% | DL |
| 6 | Raynaud disease | 88.54% | DL |
| 7 | Ambras type hypertrichosis universalis congenita | 87.79% | DL |
| 8 | obsolete susceptibility to ischemic stroke | 87.28% | DL |
| 9 | malformation syndrome with odontal and/or periodontal component | 80.46% | DL |
| 10 | stroke disorder | 79.21% | DL |
| 11 | adrenal gland hyperfunction | 79.06% | DL |
| 12 | cytomegalovirus infection | 77.76% | DL |
| 13 | syndrome with a Dandy-Walker malformation as major feature | 77.38% | DL |
| 14 | duodenogastric reflux | 77.26% | DL |
| 15 | isolated genetic hair shaft abnormality | 76.89% | DL |
| 16 | duodenal obstruction | 75.85% | DL |
| 17 | ABri amyloidosis | 75.06% | DL |
| 18 | tinea manuum | 73.92% | DL |
| 19 | hypercarotenemia and vitamin A deficiency, autosomal recessive | 72.34% | DL |
| 20 | hypertrichosis (disease) | 71.47% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.